The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known.
In this study, researchers from Boston, Massachusetts, illustrated how a single infusion of the VEGF-specific antibody bevacizumab influences rectal carcinoma.
|Bevacizumab decreases tumor perfusion in rectal cancer.|
They determined that bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells.
Dr Christopher Willett's team concluded, "These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors".